Bifunctional Peptides Inhibit HIV Entry via Dual gp41 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs, such as T20, face challenges due to rapid emergence of resistant viruses, painful injection-site reactions, high production costs, and limited effectiveness against T20-resistant strains, necessitating the development of more potent and stable anti-HIV agents.
Innovation Solution
Design and expression of bifunctional molecules comprising C-terminal heptad repeat (CHR) peptides with pocket-binding and heptad repeat-binding domains linked by flexible linkers, which target the HIV gp41 NHR region and lipid membranes, enhancing stability and potency against resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T20 is used as an anti-HIV drug, then HIV entry is inhibited, but T20-resistant viruses emerge rapidly
Solution Approach 1:
The patent combines two functional domains into a single bifunctional molecule: a pocket-binding domain (PBD) that binds to the gp41 NHR region and an HR-binding domain (HBD) that binds to the same region. This combination creates a synergistic effect where the PBD anchors the molecule to the virus while the HBD provides additional binding strength and stability, preventing resistance emergence more effectively than T20 alone.
Solution Approach 2:
The bifunctional molecule is designed as a composite peptide structure with distinct functional regions: the PBD (residues 626-635) containing the pocket-binding motif, the HBD (residues 636-665) containing heptad repeat binding sequences, and a flexible linker. This composite structure allows the molecule to simultaneously interact with multiple sites on gp41, creating a more stable complex that resists viral mutation and resistance development.
2Reliability
If T20 is administered at high dosage, then HIV entry inhibition is enhanced, but injection-site reactions increase
Solution Approach 1:
The patent changes the molecular parameters of the anti-HIV agent by creating a bifunctional structure with enhanced binding affinity. The PBD provides strong anchoring to the gp41 pocket-forming sequence while the HBD provides additional interaction sites, resulting in higher binding affinity at lower concentrations. This reduces the required dosage from T20's 90 mg/dose to potentially lower doses of the bifunctional molecule, thereby reducing injection-site reactions.
3Reliability
If synthetic peptide T20 is produced, then anti-HIV activity is achieved, but production cost becomes exorbitant
Solution Approach 1:
The bifunctional molecule is designed with modular functional domains that can be produced separately and then linked. The PBD and HBD are distinct functional segments that can be synthesized independently using standard peptide synthesis methods, and then joined through the flexible linker. This segmentation allows for more efficient production and potential cost reduction compared to synthesizing T20 as a single continuous peptide, as each domain can be optimized for its specific function.
4Reliability
If T20 binds to gp41 NHR region, then HIV fusion is blocked, but binding strength is insufficient to compete with viral gp41 CHR-NHR interaction
Solution Approach 1:
The patent merges two binding mechanisms into one molecule: the PBD binds to the pocket-forming sequence in the NHR region, providing anchoring, while the HBD binds to the same NHR region through heptad repeat interactions. This dual binding mechanism creates a synergistic effect where the combined binding strength of PBD and HBD exceeds that of T20 alone, enabling the bifunctional molecule to effectively compete with and displace the viral gp41 CHR-NHR interaction, thereby blocking fusion more effectively.
Data Source
AI summary
Disclosed herein are bifunctional molecules which inhibit HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV, including non-B and multi-drug resistant strains.